Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model. by Chatterjee, Diptaman et al.
ARTICLE OPEN
Proteasome-targeted nanobodies alleviate pathology and
functional decline in an α-synuclein-based Parkinson’s disease
model
Diptaman Chatterjee1, Mansi Bhatt1, David Butler2,3, Erwin De Genst4, Christopher M. Dobson4, Anne Messer2,3 and
Jeffrey H. Kordower1,5
Therapeutics designed to target α-synuclein (α-syn) aggregation may be critical in halting the progression of pathology in
Parkinson’s disease (PD) patients. Nanobodies are single-domain antibody fragments that bind with antibody specificity, but allow
readier genetic engineering and delivery. When expressed intracellularly as intrabodies, anti-α-syn nanobodies fused to a
proteasome-targeting proline, aspartate or glutamate, serine, and threonine (PEST) motif can modulate monomeric concentrations
of target proteins. Here we aimed to validate and compare the in vivo therapeutic potential of gene therapy delivery of two
proteasome-directed nanobodies selectively targeting α-syn in a synuclein overexpression-based PD model: VH14*PEST (non-
amyloid component region) and NbSyn87*PEST (C-terminal region). Stereotaxic injections of adeno-associated viral 5-α-syn (AAV5-
α-syn) into the substantia nigra (SN) were performed in Sprague–Dawley rats that were sorted into three cohorts based on pre-
operative behavioral testing. Rats were treated with unilateral SN injections of vectors for VH14*PEST, NbSyn87*PEST, or injected
with saline 3 weeks post lesion. Post-mortem assessments of the SN showed that both nanobodies markedly reduced the level of
phosphorylated Serine-129 α-syn labeling relative to saline-treated animals. VH14*PEST showed considerable maintenance of
striatal dopaminergic tone in comparison to saline-treated and NbSyn87*PEST-treated animals as measured by tyrosine hydroxylase
immunoreactivity (optical density), DAT immunoreactivity (optical density), and dopamine concentration (high-performance liquid
chromatography). Microglial accumulation and inflammatory response, assessed by stereological counts of Iba-1-labeled cells, was
modestly increased in NbSyn87*PEST-injected rats but not in VH14*PEST-treated or saline-treated animals. Modest behavioral
rescue was also observed, although there was pronounced variability among individual animals. These data validate in vivo
therapeutic efficacy of vector-delivered intracellular nanobodies targeting α-syn misfolding and aggregation in synucleinopathies
such as PD.
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INTRODUCTION
Synucleinopathies are a class of neurodegenerative diseases
featuring misfolding and disordered aggregation of the protein,
α-synuclein (α-syn). Parkinson’s disease (PD) is the most common
of these disorders and is primarily characterized by significant loss
of dopaminergic neurons in the substantia nigra (SN) and
abrogation of dopaminergic tone along the nigrostriatal path-
way.1,2 A prominent neuropathological hallmark of PD is the
presence of α-syn centric intracellular inclusions throughout the
brain, called Lewy bodies and Lewy neurites.3,4 Although the
precise mechanisms of α-syn-mediated neurotoxicity are still
unknown, findings suggest that overexpression of α-syn in concert
with encumbered chaperone activity and dysfunctional protein
degradation machinery may trigger aggregation and cellular
disruption.5–9 Furthermore, mounting evidence of direct cell-to-
cell transmission of toxic α-syn species lends weight to the theory
of prion-like spatiotemporal progression of pathology.10–12 Thus,
methods to interrupt proteinaceous inclusion formation and
proteopathic seeding represent promising paradigms for ther-
apeutic interventions.
Currently, efforts to mediate α-syn toxicity have primarily
utilized α-syn-targeting immunoglobulins to neutralize extracel-
lular transmission of propagating species.13–16 However, uncover-
ing methods to probe and impede intracellular induction of
proteinopathy in the PD brain is a significant challenge for long-
term, lasting remediation of α-syn toxicity. Intrabodies, either in
single-chain variable fragment form or single-domain immuno-
globulin fragments (VH, VHH, or VL), provide a novel therapeutic
approach for intracellular targeting of disordered antigens in
neurological disease.17 Numerous candidate intrabodies have
been selected and tested in vitro targeting various species of α-
syn, including monomeric, oligomeric and protofibrillar, and
fibrillar forms (reviewed by: Bhatt et al.18 and De Genst et al.19).
Previously we have characterized in situ efficacy of two primary
aptamer nanobodies, VH14 (otherwise referred to as NAC14)20 and
NbSyn87,21 to interfere with mutant α-syn aggregation events and
dampen model system proteostatic burden.22
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VH14 was screened from a public access, yeast surface display
library and has a high-binding affinity for the hydrophobic non-
amyloid component region of monomeric α-syn (Fig. 1a, c) found
to be critical in fibril formation.20 VH14 is a nanobody derived from
human origin, making it a prime candidate for evading
immunogenicity and inflammatory perturbation in the context
of clinical PD. NbSyn87 is a fully camelid nanobody selected from
a phage display library.23 NbSyn87 belongs to a class of nanobody
aptamers that target the C-terminal region of α-syn (Fig. 1c, d) that
is known to be the site of post-translational modifications
affecting pathogenic triggers of misfolding.24 As the C-terminal
tail of α-syn remains exposed in oligomeric and protofibrillar
species of aggregated complexes, NbSyn87 provides the added
benefit of binding to both monomeric and early fibrillar forms of
α-syn, although epitope affinity is markedly reduced in advanced
maturation stages.21 Moreover, NbSyn87 and another nanobody,
NbSyn2, which are both specific for the C-terminal region of α-syn,
have been shown to inhibit the formation of toxic oligomers
in vitro and protect against the toxic action of these oligomers in
cell culture models.25
Nanobody aptamers independent of stabilizing light-chain
fragments are often poorly soluble and prone to aggregation,
potentially exacerbating the proteostatic burden in the context of
the PD neuraxis. Previously, we have validated enhanced nano-
body solubility by engineering a polypeptide tether construct rich
in proline, aspartate or glutamate, serine, and threonine (PEST)
residues.22,26,27 The fusion of the PEST motif decreases the overall
net charge and isoelectric point of the protein nanobody
improving soluble aptamer expression and effective concentra-
tions in vitro. PEST constructs also act as ubiquitin-independent
proteosomal-targeting motifs capable of rapidly degrading bound
antigen. We have previously confirmed that the fusion of a PEST
degron, derived from a murine ornithine decarboxylase protein, to
both VH14 and NbSyn87 efficaciously stalls α-syn aggregation,
mediates proteasomal clearance of α-syn, and attenuates proteo-
pathic stress.22
Here, we demonstrate in vivo, proof-of-concept efficacy data of
two candidate intrabodies, VH14*PEST and NbSyn87*PEST,
delivered by gene therapy to a viral α-syn overexpression rodent
model of PD. This study validates the proposition that both
engineered nanobodies can reduce aggregation of α-syn and limit
the expression of α-syn species phosphorylated at Serine-129 (p-
S129) correlative of pathological aggregation. Additionally, our
data suggest that VH14*PEST α-syn targeting attenuates func-
tional indices reflective of nigrostriatal dopaminergic integrity.
These data corresponded with modest preservation in gross
Fig. 1 Experimental design and study overview. a Study design: genes expressing intrabodies or saline vehicle were delivered by viral vector
into animals previously lesioned with an α-syn overexpression vector for observation of treatment effects on behavior and post-mortem
analysis of pathology. b Model overview of α-syn overexpression via viral vector delivery of human α-syn into the substantia nigra pars
compacta (scale bar: B—50μm). c Schematic of α-syn protein and target regions for nanobody aptamers VH14*PEST and NbSyn87*PEST. d
Diagram of the process of α-syn fibril formation, sites of intrabody binding, and intrabody-mediated protein clearance mechanisms
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motor behavior in the VH14*PEST-treated cohort. Although
displaying inferior rescue of striatal dopaminergic output mea-
sures in comparison with VH14*PEST, NbSyn87*PEST treatment
also showed indications of protected motor function. Collectively,
these data provide a platform for further pre-clinical screening of
α-syn targeting intrabodies as potential therapeutics for PD and
other synucleinopathies.
RESULTS
VH14*PEST and NbSyn87*PEST expression reduces pathologic
aggregation of α-syn
To model α-syn-based proteinopathy, we utilized a viral vector
overexpression model of human wild-type α-syn. All subjects
received a unilateral injection of an AAV5-α-syn construct directly
into the substantia nigra (Fig. 1b). Contralateral hemispheres were
not injected and used as controls for lesioned hemispheres. To
equilibrate baseline functional performance, lesioned animals
were pre-sorted into treatment groups based on baseline
behavioral function (Fig. 4). Untreated lesions generated consis-
tent, unilateral Lewy body-like inclusions (Fig. 1b) in the soma and
neurites of injected nigral neurons. These protein bodies were
resistant to proteinase K digestion, indicating insoluble α-syn
inclusions representative of pathologic aggregates (Fig. S2). Three
weeks post lesion, animals were injected with viral vectors
expressing VH14*PEST or NbSyn87*PEST, or were injected with
an equivalent volume of control saline. Histological analysis of
post-mortem tissue revealed significant (p < 0.05) reduction in
labeling of p-S129, as measured densitometrically relative to the
unlesioned side (Fig. 2a, b). VH14*PEST and NbSyn87*PEST
treatment produces a near twofold reduction of relative patho-
logical aggregate labeling compared to saline treatment of lesions
(Fig. 2b). Inclusion formation is markedly reduced in both
nanobody-treated groups, with VH14*PEST displaying robust
reduction of p-S129 labeling (Fig. 2a, inset). Dual immunofluor-
escent labeling of p-S129 α-syn and Thioflavin-S validates the
labeling of p-S129 residues corresponding with β-sheet aggrega-
tion, as is the case in authentic Lewy body pathology (Fig. 2c).
Due to some contralateral background staining observed in p-
S129 staining in the SN, we stained for human-specific α-syn
species (LB509) to confirm the expression of vector-derived α-syn
on the side of lesioning (Fig. S1a). Robust expression of α-syn was
predominantly localized ipsilateral to the site of lesion (Fig. S1a).
Densitometric measurement of LB509-labeled α-syn in the SN did
not reveal statistically significant changes in treatment groups,
although there were slight non-significant decreases for both
VH14*PEST-treated and NbSyn87*PEST-treated cohorts (Fig. S1b).
Taken together, these data demonstrate that both intrabodies
reduce α-syn protein concentration at a permissive rate for
inhibited proteopathic aggregation but do not excessively clear α-
syn species to the point of phenotypic loss of function.
VH14*PEST halts α-syn-induced pathology afflicting nigrostriatal
dopaminergic tone
Given the success of both intrabodies in governing α-syn
aggregation, we next aimed to evaluate nigrostriatal pathology
central to canonical PD phenotype. Histological analysis of
tyrosine hydroxylase (TH) labeling in the striatum revealed
significant preservation of synaptic innervation in VH14*PEST-
treated animals compared to both saline-treated and NbSyn87*-
PEST-treated animals (Fig. 3a). TH+ deficiency of the lesioned
hemispheres was more prominent in the dorsolateral region of the
striatum (Fig. 3a). By contrast, relative quantitation of VH14*PEST-
treated animals showed a 49% increase in striatal TH+labeling
compared to saline-treated animals and a 38% increase compared
to NbSyn87*PEST-treated animals. Histological analysis of TH
labeling in the striatum revealed significant preservation of
synaptic innervation in VH14*PEST-treated animals compared to
both saline-treated and NbSyn87*PEST-treated animals.
Next, we evaluated the stereological density of TH+-labeled
cells in the SN (Fig. 3a). In our hands, 4-month post-model
induction was insufficient time to see significant loss in nigral
dopaminergic neurons in lesioned hemispheres, as has been
previously reported.28 However, intrabody treatment shows a
trend in neuroprotection by one-way analysis of variance (ANOVA)
comparison of p values between lesioned and contralateral
control nigral neuron densities (Fig. 3c). To establish a more
complete profile of striatal dopaminergic capacity, we stained
sections for dopamine transporter (DAT) expression (Fig. 3b).
Consistent with the TH data, the VH14*PEST-treated cohorts
showed modest protection of overall DAT expression with a 28%
increase in optical density relative to control expression (Fig. 3c).
NbSyn87 treatment also ameliorated both TH and DAT expression,
but at statistically insignificant levels (Fig. 3a–c). To determine the
overall supply of striatal dopamine, tissue of eight animals from
each cohort was processed by high-performance liquid chroma-
tography to determine relative dopamine concentrations.
Although changes in striatal dopamine supply were statistically
insignificant, median dopamine concentration in VH14*PEST-
treated animals relative to the control hemispheres was ~3-fold
higher than that of the saline-treated group (p= 0.13) (Fig. 3c).
Individual subjects had dynamic variability in the total dopamine
concentrations recorded.
To appraise intrabody-mediated changes to nigrostriatal output,
we evaluated motor phenotype via two behavioral assays
throughout the study: the stepping test and the cylinder test.
VH14*PEST-treated animals showed significant (p < 0.05) improve-
ment in motor behavior compared to saline-treated control in
stepping test performance at the study endpoint (Fig. 4a, b). In
contrast to histopathological evaluation of nigrostriatal tone,
NbSyn87*PEST-treated animals showed improved rescue of the
motor phenotype. NbSyn87*PEST-treated animals displayed sig-
nificant increases in stepping test contralateral forelimb contacts
in comparison to lesioned saline controls from 2-week post lesion
through to the study endpoint (Fig. 4a, b). NbSyn87*PEST-treated
animals showed less rapid preservation of motor behavior in the
cylinder test performance compared to saline controls, only
displaying significant improvement 6 weeks post lesion (Fig. 4c, d).
In both behavioral assays, no statistically significant differences
were found in motor performance between both intrabody-
treated cohorts. Individual animal performance in both intrabody
cohorts was highly variable, coinciding with the pronounced
variance in striatal dopamine levels (Fig. 4b, d). Collectively, these
data show VH14*PEST treatment to elicit significant preservation
of multiple indices of nigrostriatal health and pathway main-
tenance in the context of induced synucleinopathy. However, the
NbSyn87*PEST-treated group, although showing minimal evi-
dence of dopaminergic rescue, only modestly conserved overall
motor function.
NbSyn87*PEST elicits inflammatory response in lesioned SN
A critical aspect of gene therapy and immunoglobulin-derived
treatment constructs is immunogenicity and a potentiated
inflammatory response to treatment. To evaluate potential
inflammation, we investigated the recruitment and activity of
microglia to sites of injection in the SN. We immunolabeled the
microglial calcium-binding protein marker, Iba-1, as a reporter of
resident macrophage activation (Fig. 5). In comparison to
unlesioned contralateral hemispheres, treated hemispheres of
both the saline and VH14*PEST cohorts showed statistically
insignificant increases in total microglial density, as measured
stereologically (22 and 13%, respectively) (Fig. 5b). However,
NbSyn87*PEST treatment induced a 63% increase in microglial
density compared to controls (Fig. 5b). Consistent with these
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findings, microglia in the SN of NbSyn87*PEST-treated animals
appear amoeboid in morphology, generally indicative of phago-
cytic macrophage activity (Fig. 5a, inset, red arrows). By contrast,
observations of microglial morphology for saline-treated and
VH14*PEST-treated animals preserve the canonical ramified,
inactive shape (Fig. 5a, inset). These assessments implicate
NbSyn87*PEST as a potential inducer of inflammatory response,
although further investigation of glial surface markers and signal
transduction is necessary to reveal a true immune response.
DISCUSSION
Currently, there are no disease-modifying clinical therapies being
used directly to combat the synucleinopathy central to PD
pathogenesis. Numerous recent efforts have aimed to halt
pathogenic cellular propagation of fibrillar species through
immunotherapy with promising success.13–16,29 However, immu-
notherapeutic modalities fail to adequately address the intracel-
lular pathogenic cascade. Improper α-syn nucleation and
oligomerization at axon terminals are central to mechanistic
implications of PD pathology.30 Clearance of extracellular α-syn
deposits may not actively prevent stochastic intracellular seeding
and degenerative pathway activation.31,32 Furthermore, active
pathways employed by therapeutic biologics for α-syn clearance
may be functionally perturbed in PD cellular environments.33–35
Thus, the prevention of intracellular aggregation and maintenance
of intracellular concentrations is critical in reversal of neurotoxicity.
We have previously shown that both VH14*PEST and NbSyn87*-
PEST were effective in reducing excess α-syn accumulation and
limiting α-syn-mediated neurotoxicity in vitro.22 Proteins contain-
ing a PEST motif are often targeted for proteasomal degradation.
Fusion of the PEST degron to anti-huntingtin intrabodies targets
them and their intracellular cargo to the proteasome for
degradation based on proteasome inhibition with specific
proteasome inhibitor epoxomicin.27 Additionally, scrambling the
PEST motif successfully eliminates the clearance of both the
intrabody and its intracellular cargo.27 These findings have also
been replicated with the VH14*PEST and NbSyn87*PEST con-
structs used in this study.22 For these targets to be degraded
through the proteasome, they must remain soluble,36 which
intrabody binding facilitates. When binding to the proteasome the
cargo is degraded along with the short (<200 amino acids)
nanobody. Although it is difficult to resolve the relative
contributions of intrabody interference of target epitopes or
proteasomal substrate clearance in the observed anti-
amyloidogenesis effect of this study, our in vitro data leads us
Fig. 2 Nanobody expression significantly reduces induced pathological synucleinopathy. a Labeling of phosphorylated Serine-129 α-syn
species in the substantia nigra reveals reduction of pathological aggregates in both intrabody-treated cohorts compared to saline controls.
Intrabody treatment also reduces the overall level of mature Lewy body-like cellular aggregates (inset) (scale bars: 100 and 25 μm). b
Quantification of optical density measurements of phospho-Serine-129 labeling in the substantia nigra. Both VH14*PEST and NbSyn87*PEST
treatment groups reveal significant decreases in densitometric labeling of pathological α-synuclein species. The data were analyzed via one-
way ANOVA with Tukey's post hoc comparisons (saline—n= 8, VH14*PEST—n= 7, NbSyn87*PEST—n= 7, all *p < 0.05). c Dual
immunofluorescent labeling of phosphorylated Serine-129 and Thioflavin-S confirms that phosphorylated residues are representative of
aggregated α-syn species (scale bar: 100 μm)
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to hypothesize PEST-mediated α-syn clearance to be an essential
factor in disaggregation.
Addition of the PEST degron to both nanobody aptamers
enhanced hydrophilicity and decreased overall molecular charge
to stabilize soluble constructs, allowing for superior α-syn
targeting and proteosomal clearance.26 Consistent with these
data are our findings of intrabody-mediated α-syn clearance and
diminution of pathologic α-syn labeling in the SN (Fig. 2a, b). With
Thioflavin-S staining of β-sheet aggregation, we confirmed p-
S129-labeled species to be indicative of toxic aggregates and a
representative marker for histopathology (Fig. 2c). Due to limited
tissue material we were unable to appropriately quantify
reductions in Thioflavin-S staining by stereology, although we
were able to qualitatively observe reductions in aggregation in
both intrabody-treated cohorts. We determined in previous in situ
characterizations of these two candidate intrabodies that although
NbSyn87*PEST clears α-syn more effectively than VH14*PEST,
VH14*PEST modifies cellular stress associated with multi-factorial
proteostasis to a greater extent, particularly in the case of α-syn
promotion of mutant huntingtin proteinopathy.22 This aspect of
intervention is integral for synucleinopathies that are commonly
associated with concomitant pathology of additional proteins
vulnerable to disordering or misfolding such as tau, amyloid-β,
and mutant huntingtin. Abating proteostatic stress in PD, where
both chaperone-mediated autophagic and macro-autophagic
systems are perturbed and changes in cellular oxidation accelerate
misfolding, may be a complementary clinical target to α-syn
toxicity.5,30,33,34
This study aimed to use intrabody treatment to modify
synucleinopathy in the context of canonical Parkinsonian motor
pathology. Nigrostriatal pathology in PD is a complex process that
is difficult to accurately and temporally model. Clinical PD begins
as an axonopathy in which striatal terminal depletion and
subsequent neurotransmittive failure provokes phenotypic
onset.37–39 One of the α-syn’s primary roles in striatal axonopathy
is phenotypic insult through synaptic injury.37–41 To that end, our
model represents early PD-like pathology in which striatal
innervation loss can clearly be observed through reductions in
TH and DAT immunoreactive densities and depleted levels of
striatal dopamine (Fig. 3). These deficits were directly correlated to
α-syn aggregation that featured classical β-sheet amyloid
organization (Thioflavin-S) and was resistant to Proteinase K
Fig. 3 VH14*PEST treatment counteracts insults in nigrostriatal dopaminergic tone induced by synucleinopathy. a Assessment of TH+
immunoreactivity in the substantia nigra and striatum. VH14*PEST reveals preservation of striatal innervation in comparison to saline-treated
and NbSyn87*PEST-treated animals. Evidence of protection is strongest in the dorsolateral striatum (scale bars: 100 and 25 μm). b
Immunostaining of dopamine transporter (DAT) expression in the striatum shows modest improvement in VH14*PEST treatment animals
compared to saline-treated animals (scale bar: 25 μm). c Quantification of striatal TH optical density (saline—n= 7, VH14*PEST—n= 7,
NbSyn87*PEST—n= 8), stereological cell counts of TH-labeled cells in the substantia nigra (saline—n= 7, VH14*PEST—n= 8, NbSyn87*PEST
—n= 7), striatal DAT optical density (saline—n= 7, VH14*PEST—n= 8, NbSyn87*PEST—n= 7), and the concentration of striatal dopamine
(saline—n= 4, VH14*PEST—n= 7, NbSyn87*PEST—n= 6). All data were analyzed via one-way ANOVA with Tukey's post hoc comparisons (all
*p < 0.05, **p < 0.01, or as indicated on figure)
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digestion, validating the vector-induced accumulation as authen-
tic Lewy body-like deposition (Fig. S2). Although our model did
not feature nigral neuron loss at the time of animal sacrifice, the
striatal deficits that were observed serve as early hallmarks of
pathology and most likely precede downstream nigral neurode-
generation. Furthermore, evidence from the VH14*PEST cohort
demonstrates that intrabody treatment can directly counteract
and rescue nigrostriatal terminals from the early-phase, PD-like
pathology observed in the saline-treated animals.
It is unclear why, although both intrabodies successfully
remediated pathogenic aggregation of α-syn, VH14*PEST showed
superior histological conservation of the nigrostriatal pathway,
featuring protection of striatal integration, preserved expression of
striatal DAT, and trending conservation of dopaminergic nigral
neurons and striatal dopamine supply. One explanation may be
the increased inflammatory signaling observed in the NbSyn87*-
PEST-injected SN which may exacerbate α-syn-induced pathology
or counteract the expected effects of reduced α-syn aggrega-
tion.42–44 The minor increases in Iba-1-labeled cells in the saline
and VH14*PEST-treated cohorts may be attributed to synuclein-
mediated inflammation. The derivation of both nanobodies from
different host species, human and camelid, provides a potential
explanation in the divergent inflammatory reactions observed
through microglial dynamics. The lower inflammatory response
observed in the VH14*PEST group, combined with its human
origin, suggests that this nanobody construct may be a more
conservative therapeutic option. Stabilized inflammatory activa-
tion in the VH14*PEST treatment group also implies that viral
delivery did not elicit nigral inflammation ipsilateral to injection.
These data from the VH14*PEST cohort also validate that repeated
injection with AAV5 virus alone does not induce stable, long-term
inflammation. However, further analysis of microglial surface
markers and monocyte expression is necessary to characterize any
induction of active inflammation or potentiatiation of an immune
response. Interestingly, NbSyn87*PEST treatment showed a
modest improvement over VH14*PEST in functional preservation
in behavioral assays, in contrast to indications of ineffectual
nigrostriatal dopaminergic preservation. These findings may be a
result of pronounced variability in individual animal performance
in both the cylinder test and the stepping test and may
necessitate a lengthier lesion procedure for future experimental
iterations or deeper investigation of fine motor coordination, such
as gait analysis.45
An exciting attribute of intrabody therapy is the use of viral
vector delivery systems as a primary modality for long-term
treatment. The use of AAV vectors to deliver long-term,
recombinant payloads to combat neurological disease may be
ideal for prolonged, age-related neurodegeneration.46–48 Potential
Fig. 4 Nanobody treatment induces functional motor recovery. a Results of stepping test behavior to assess unilateral forelimb akinesia
induced by synucleinopathy and intrabody treatment effects. Both intrabody-treated cohorts improve use of forelimbs contralateral to site of
lesion. b Box-and-whisker graph of study-endpoint stepping test behavioral performance. c Results of cylinder test behavior to assess
unilateral forelimb akinesia and intrabody treatment effects. d Box-and-whisker plot of study-endpoint cylinder test behavioral performance.
All the data were analyzed via two-way ANOVA with Tukey's post hoc comparisons (saline—n= 14, VH14*PEST—n= 15, NbSyn87*PEST—n=
14, all p values reported are comparisons with control subjects: *p < 0.05, ***p < 0.001, #p < 0.05, or as indicated on the figure. No significant
findings were observed in comparison with intrabody-treated cohorts)
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cell replacement strategies for PD treatment may still require anti-
α-syn therapeutic strategies, as toxic α-syn species have been
shown to propagate into cell graft material.11 Intrabodies
transduced into these cells pre-transplantation could protect
grafted cells from host-transmitted synucleinopathy. However, a
primary concern with gene therapy intrabody treatment, particu-
larly with the deployment of proteosomal clearance mechanisms,
is the effective titer and dosing paradigm required to reverse
abnormal physiological concentrations of monomeric α-syn.
Although early studies suggested minimal neurophysiological
importance of α-syn expression,49 current data suggest that
subthreshold knockdown of α-syn can induce dose-dependent
neurodegeneration and functional decline in neurotransmis-
sion.50,51 Intrabody binding to α-syn may also interrupt physiolo-
gical functional capacities, primarily in membrane-binding
domains critical for vesicular trafficking and SNARE (soluble N-
ethylmaleimide-sensitive factor activating protein receptor) com-
plex arbitration.52,53 NAC region binding, as is the case for
VH14*PEST, may be particularly conducive to loss-of-function α-
syn interference in overdosed, prolonged expression systems. Our
analysis of VH14*PEST, delivered at a high titer of 1 × 1013 vg/ml,
revealed no exacerbation of α-syn phenotypic insults. Further-
more, the lack of statistically significant decrease in human-
specific α-syn species, as denoted by LB509+ labeling (Fig. S1),
suggests that the expression of VH14*PEST and NbSyn87*PEST is
adequate for pathologic prevention based on the degree of α-syn
overexpression in this model and maintains supra-threshold α-syn
concentrations for proper function. These findings minimize
concern of the potential for viral “overshoot” that may dispro-
portionately induce excessive and detrimental clearance of α-syn,
thus allowing for future studies exploring alternative delivery
methods and higher-order model systems.
To date, nanobody technology has not been prominently
utilized in in vivo settings. Although antibody fragments are high-
affinity binders that optimize target specificity, in vitro aptamer
stability has been difficult to reproduce in the cellular milieu of live
animal models. The use of ER-tethered nanobodies to specifically
halt transduction of protein products through the secretory
pathway has shown early promise in loss-of-function targeting
of toxic proteins in the context of Alzheimer’s disease and tumor-
induced angiogenesis.54 Through our use of the PEST motif, we
were able to stabilize our constructs in a reductive cellular
environment to potentially overcome this hurdle while maintain-
ing cytosplasmic scavenging potential. Perhaps the most frequent
application of in vivo nanobody utilization has been in nanobody-
assisted tumor-imaging modalities for cancer-specific cellular
markers.54–56 However, effective use of nanobody technology in
direct target protein interference has been slow. A recent report
has shown nanobody efficacy in anti-fibrillarization of circulating
β2-microglobulin in transgenic mice modeling genetic forms of
hemodyalisis, although these nanobodies were targeting circulat-
ing protein aggregation.57 Our study is among the first to employ
a gene therapy intrabody system that can specifically target
amyloidogenesis of cytosolic protein within the central nervous
system parenchyma.
In the context of progressing intrabody therapy into transla-
tional studies, it is important to evaluate the model system in
which this set of experiments was conducted, as well as the
timeline of potential therapeutic intervention. Our use of the AAV-
α-syn overexpression model was intended to determine the
baseline efficacy of intrabody therapy on pathologic aggregation.
However, clinical observation of disease is significantly delayed
compared to pathogenic onset and proteopathic seeding events.
A supplemental, clinically relevant experimental paradigm may
also include a model utilizing pre-formed α-syn aggregates to
mimic toxic cell-to-cell propagation dynamics, prion-like seed
propensity, and optimize α-syn substrate clearance.58,59 Addition-
ally, growing consideration for peripheral sources of α-syn
deposition, in particular via the gut–brain axis, warrant considera-
tion of a global therapeutic paradigm for intracellular α-syn
intervention.60–62 Our study design has served as a proof-of-
principle investigation into nanobody perturbation of modeled PD
pathophysiology, primarily nigrostriatal neurotoxicity. However,
clinical PD, particularly α-syn centric pathology, occurs throughout
the neuraxis with prevalent manifestation of extra-motor pheno-
types. Recent reports illuminating advanced transduction effi-
ciency throughout the central nervous system and periphery via
engineered AAV capsids open the door for intrabody targeting of
widespread α-syn pathology potentially through intrathecal or
intravenous administration, enhancing the translational potential
for clinical paradigms.63 The data presented in this study, in
conjunction with extracellular protein clearance mechanisms,
highlight an intriguing avenue for disruption of α-syn toxicity
and targeted relief of proteostatic insult in neurological disease.
MATERIALS AND METHODS
Animals
All care and husbandry of animal subjects was carried out in accordance
with protocols approved by the Institutional Animal Care and Use
Committee at Rush University Medical Center. Forty-eight, 8-week-old
Sprague–Dawley rats (Harlan Biotechnology) were maintained under a 12-
hour light–dark cycle at 25 °C and 50% humidity. Animals were fed ad
libitum chow and water. All animals used in the study were acclimatized in
the testing facility for 1 week prior to initiation of experimentation.
Fig. 5 NbSyn87*PEST treatment elicits inflammatory response in substantia nigra. a Immunolabeling of Iba-1 in the substantia nigra reveals
microglial recruitment and activation. NbSyn87*PEST treatment induces higher levels of microglial clustering to the injected substantia nigra
than in VH14*PEST-treated animals. NbSyn87*PEST-treated animals also exhibit higher populations of amoeboid microglia indicating active
microglial morphology (red arrow, inset) (scale bars: 100 and 25 μm). b Stereological quantification of Iba-1 labeled cells indicates significant
increases in microglial recruitment in NbSyn87*PEST, representative of a stronger inflammatory response. Data were analyzed via one-way
ANOVA with Tukey's post hoc comparisons (saline—n= 6, VH14*PEST—n= 8, NbSyn87*PEST—n= 7, all *p < 0.05, **p < 0.01)
Proteasome-targeted nanobodies alleviate pathology and functional
D Chatterjee et al.
7
Published in partnership with the Parkinson’s Foundation npjParkinson’s Disease (2018)  25 
Behavioral assays
Rodent behavioral tests were performed as previously described.64
Modified cylinder tests and stepping tests were performed 1 week prior
to lesioning and 2 weeks post lesion to establish baseline performance
scores. Animals were pre-sorted into treatment groups based on post-
lesion performance scores. Behavioral assays were conducted bi-weekly
after treatment injections until the study end date after week 17.
Performance for both tests was assessed by analyzing the percentage of
forelimb contacts contralateral to the side of lesion.
Stereotaxic surgery
All stereotaxic surgical procedures were followed as previously
described.65 Animals were anesthetized with sodium ketamine hydro-
chloride (100mg/kg)/xylazine hydrochloride solution (10 mg/kg). All
subjects were lesioned via unilateral injections of AAV5-α-synuclein
(volume: 2 μl, vector titer: 1 × 1012 vg/ml, UNC Vector Core) into the right
substantia nigra (Coordinates: A/P at −4.8 mm, M/L at 1.7 mm, and D/V at
−7.5 mm) at a flow rate of 0.2 μl/min. Animals were sorted into three
treatment groups based on post-lesion behavioral performance, and a
second round of surgeries were performed 3 weeks post lesion. Groups 1
and 2 received intranigral injections (volume: 2 μl, vector titer: 1 × 1013 vg/
ml, UNC Vector Core) at a flow rate of 1.0 μl/min of AAV5-VH14*PEST and
AAV5-NbSyn87*PEST, respectively. Group 3 received an injection of vehicle
saline at the same injection conditions.
Rodent necropsy and tissue processing
At the study endpoint, animals were anesthetized with and perfused
transcardially with 0.9% sterile phosphate-buffered saline (PBS) solution or
4% paraformaldehyde solution at 4 °C. Brains perfused with PBS were snap
frozen for high-performance liquid chromatography (HPLC) processing.
Brains perfused in 4% paraformaldehyde were post-fixed overnight in 4%
paraformaldehyde solution and subsequently transferred to a 10, 20, and
30% sucrose gradient until the tissue sank. Brains were maintained in
sucrose solution until they were cut on a freezing-stage sliding microtome
into 40 μm coronal sections. Sections were stored in cryopreservative
solution until immunohistochemical processing.
High-performance liquid chromatography
All HPLC protocols were followed as previously described.66 Striata from
eight animals in each cohort were extracted, processed, and analyzed for
concentrations of dopamine. Tissue was sonicated in 0.2 M perchloric acid
with isoproterenol. Centrifuged supernatant was injected in a Eicompak
SC-3ODS column (JM Science, Inc.) and analyzed as per the manufacturer’s
protocol.
Immunohistochemistry, Proteinase K, and Thioflavin-S staining
All immunohistochemistry protocols were followed as previously
described.65 Free-floating sections (40 μm) of coronal brain slices were
stored in cryoprotectant and quenched with sodium periodate prior to
staining. Sections for immunohistochemistry were incubated with the
primary antibodies listed in Table S1. Sections were subsequently
incubated with the respective biotinylated secondary antibodies (Table
S1) and labeled with a standard ABC HRP Biotin/Avidin Complex Kit (Vector
Laboratories). Staining was developed with DAB and sections were
mounted for imaging and analysis. Proteinase K digestion protocol was
followed as previously described.65 Briefly, sections were mounted and
dried on gelatin-coated slides. Tissue was rehydrated and incubated with
10 μl/ml of Proteinase K (Invitrogen) dissolved in TBST for 30min at 55 °C.
Sections were subsequently fixed with 4% paraformaldehyde for 10min
and immunostained for α-syn as previously described. Preceding
Thioflavin-S staining, tissue was pre-processed for phosphorylated
S129 α-syn immunofluorescence using adapted staining protocol pre-
viously described. Tissue was mounted and dried on gelatin-coated slides
at room temperature. Sections were defatted in chloroform for 2 h and
hydrated through graded alcohols. Tissue was incubated in 0.1%
Thioflavine-S solution (Sigma) for 10min prior to imaging. All immuno-
fluorescent images were taken on an Olympus confocal laser scanning
microscope with the Fluoview software.
Densitometry
Optical density measurements were taken using Scion Image (v1.63, Meyer
Instruments). Samples were imaged on an Olympus BH-2 microscope
(Olympus) and corresponding regions imaged were aligned in a reading
frame prior to recording. Densitometric measurements from a minimum of
two sections in a half-series (every 12th section) of each subject were
recorded and averaged for quantitative measurements. Data from variable
regions were normalized with in-subject, uninjected control hemispheres.
Stereology
Cell counts were estimated by unbiased stereological counting methods
using the optical fractionator probe in StereoInvestigator (v10.40, MBF
Biosciences).67 All raters were blinded to subject ID prior to analysis.
Sections were viewed on an Olympus BX51 microscope (Olympus) with
specific brain region contours detected and traced at ×4 objective and
data recordings conducted with ×60 magnification. Serial sections of
biological replicates were recorded using every 12 sections of 40 μm
coronal slices. Stereological assessments of TH+-labeled cells were used to
establish degree of lesion affecting dopaminergic neurons in the
substantia nigra. To assess quantitatively the level of inflammation at the
site of a given lesion, Iba-1+-labeled cells were also counted in the
substantia nigra.
Statistical analysis
All data are presented as mean ± SEM. All statistical analyses were
performed using the GraphPad Prism (version 7.03). Statistical differences
were determined by one-way or two-way analysis of variance, with
corrections for repeated measures as needed. Specific statistical analyses
and significant findings are noted in figure legends.
Data availability
All relevant data and analyses from this study are available from the
corresponding author upon request.
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